Candida glabrata fungemia in a diabetic patient with neurogenic bladder: Successful treatment with micafungin

Clinical Nephrology

Volumn 66, Issue 3, 2006, Pages 214-217

  Haruyama, N ^a   Masutani, K ^a   Tsuruya, K ^a   Sugiwaka, S ^a   Toyonaga, J ^a   Yao, T ^a   Goto, K ^b   Tokumoto, M ^a   Hirakata, H ^a   Iida, M ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Micafungin; Neurogenic bladder; Non albicans Candida

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; FLUCONAZOLE; GABEXATE MESILATE; GALLIUM; HEPARIN; INSULIN; MICAFUNGIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; BEZOAR; BLOOD EXAMINATION; CANDIDA GLABRATA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES CONTROL; DIABETIC PATIENT; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEVER; FOLLOW UP; FUNGEMIA; FUNGUS ISOLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYDRONEPHROSIS; INFLAMMATION; KIDNEY DYSFUNCTION; LABORATORY TEST; MALE; NEUROGENIC BLADDER; PATIENT TRANSPORT; PYELONEPHRITIS; PYURIA; REMISSION; SCINTIGRAPHY; SPUTUM EXAMINATION; URETER CATHETERIZATION; URETER STONE; URETEROSCOPY; URINALYSIS;

EID: 33748652078     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66214     Document Type: Article

References (16)

1. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002; 40: 1298-1302.
2. Gumbo T, Isada CM, Hall G, Karafa MT, Gordon SM. Candida glabrata fungemia. Clinical features of 139 patients. Medicine. 1999; 78: 220-227.
3. Haley LD. Yeasts of medical importance. Am J Clin Pathol. 1961; 36: 227-234.
4. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993; 37: 1962-1965.
5. Kohno S, Masaoka T, Yamaguchi H, Mari T, Urabe A, Ito A, Niki Y, Ikemoto H. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004; 36: 372-379.
6. Krcmery Jr VV, Krupova I, Mateicka F, Jurga L, Sulcova M, Spanik S, Kunova A, Novotny J. Candida glabrata fungemia in a tertiary institution in Slovakia. J Infect Chemother. 1999; 5: 163-167.
7. Krishnamurthy R, Aparajitha C, Abraham G, Shroff S, Sekar U, Kuruvilla S. Renal aspergillosis giving rise to obstructive uropathy and recurrent anuric renal failure. Geriatr Nephrol Urol. 1998; 8: 137-139.
8. Levin DL, Zimmerman AL, Ferder LF, Shapiro WB, Wax SH, Porush JG. Acute renal failure secondary to ureteral fungus ball obstruction in a patient with reversible deficient cell-mediated immunity. Clin Nephrol. 1975; 4: 202-210.
9. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005; 41: 975-981.
10. Papaevangelou V, Lawrence R, Kaul A, Lefluer R, Ambrosino M, Krasinski K, Borkowsky W. Acute renal failure in a human immunodeficiency virus-infected child secondary to bilateral fungus ball formation. Pediatr Infect Dis J. 1995; 14: 401-403.
11. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother. 1995; 39: 1696-1699.
12. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ and the SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program 1997 to 2000. J Clin Microbiol. 2002; 40: 852-856.
13. Schulz KMK and Bernhardt H. Dynamics of Candida isolations from humans from 1992-1995 in Greifswald, Germany. Mycoses. 1997; 40: 105-110.
14. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Thomas C, Panzer H, Dismukes WE. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000; 30: 19-24.
15. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S and the Japan Invasive Mycosis Surveillance Study Group. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004; 53: 283-289.
16. vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992; 36: 2602-2610.